| Pierce West Waychoff, DC | |
|
15256 N 75th Ave Ste 360, Peoria, AZ 85381-4761 | |
| (623) 486-2424 | |
| Not Available |
| Full Name | Pierce West Waychoff |
|---|---|
| Gender | Male |
| Speciality | Chiropractor |
| Location | 15256 N 75th Ave Ste 360, Peoria, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053582684 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 7912 (Arizona) | Primary |
| Provider Name | Afc Physical Medicine Of Gilbert, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1528345881 PECOS PAC ID: 0840450821 Enrollment ID: O20120328000950 |
News Archive
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
In the first study of its kind, researchers at Saint Louis University have demonstrated that immunization with a new vaccine could potentially prevent more than a million cases of pertussis (whooping cough) each year in adolescents and adults.
Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).
For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.
› Verified 4 days ago
| Provider Name | Afc Physical Medicine Of Mesa, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1659645679 PECOS PAC ID: 8123280716 Enrollment ID: O20120426000510 |
News Archive
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
In the first study of its kind, researchers at Saint Louis University have demonstrated that immunization with a new vaccine could potentially prevent more than a million cases of pertussis (whooping cough) each year in adolescents and adults.
Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).
For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.
› Verified 4 days ago
| Provider Name | Afc Physical Medicine Of San Tan Valley, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1457638603 PECOS PAC ID: 5496917502 Enrollment ID: O20120508000233 |
News Archive
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
In the first study of its kind, researchers at Saint Louis University have demonstrated that immunization with a new vaccine could potentially prevent more than a million cases of pertussis (whooping cough) each year in adolescents and adults.
Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).
For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.
› Verified 4 days ago
| Provider Name | Afc Physical Medicine Of Desert Ridge,pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1669731303 PECOS PAC ID: 6507016169 Enrollment ID: O20121017000609 |
News Archive
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
In the first study of its kind, researchers at Saint Louis University have demonstrated that immunization with a new vaccine could potentially prevent more than a million cases of pertussis (whooping cough) each year in adolescents and adults.
Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).
For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.
› Verified 4 days ago
| Provider Name | Afc Of Peoria Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1154668044 PECOS PAC ID: 1052557337 Enrollment ID: O20130410000427 |
News Archive
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
In the first study of its kind, researchers at Saint Louis University have demonstrated that immunization with a new vaccine could potentially prevent more than a million cases of pertussis (whooping cough) each year in adolescents and adults.
Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).
For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.
› Verified 4 days ago
| Provider Name | Afc Of Phoenix Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1619392362 PECOS PAC ID: 9335363100 Enrollment ID: O20140617002463 |
News Archive
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
In the first study of its kind, researchers at Saint Louis University have demonstrated that immunization with a new vaccine could potentially prevent more than a million cases of pertussis (whooping cough) each year in adolescents and adults.
Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).
For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.
› Verified 4 days ago
| Provider Name | Afc Of Tempe Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1255879854 PECOS PAC ID: 8729362892 Enrollment ID: O20170309001290 |
News Archive
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
In the first study of its kind, researchers at Saint Louis University have demonstrated that immunization with a new vaccine could potentially prevent more than a million cases of pertussis (whooping cough) each year in adolescents and adults.
Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).
For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.
› Verified 4 days ago
| Provider Name | Afc Of Surprise, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1255912721 PECOS PAC ID: 9133522675 Enrollment ID: O20210721003730 |
News Archive
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
In the first study of its kind, researchers at Saint Louis University have demonstrated that immunization with a new vaccine could potentially prevent more than a million cases of pertussis (whooping cough) each year in adolescents and adults.
Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).
For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.
› Verified 4 days ago
| Provider Name | Afc Of East Mesa Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1972256857 PECOS PAC ID: 1951773290 Enrollment ID: O20230214001522 |
News Archive
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
In the first study of its kind, researchers at Saint Louis University have demonstrated that immunization with a new vaccine could potentially prevent more than a million cases of pertussis (whooping cough) each year in adolescents and adults.
Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).
For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pierce West Waychoff, DC 1839 S Alma School Rd Ste 354, Mesa, AZ 85210-3028 Ph: (480) 726-2287 | Pierce West Waychoff, DC 15256 N 75th Ave Ste 360, Peoria, AZ 85381-4761 Ph: (623) 486-2424 |
News Archive
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
In the first study of its kind, researchers at Saint Louis University have demonstrated that immunization with a new vaccine could potentially prevent more than a million cases of pertussis (whooping cough) each year in adolescents and adults.
Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).
For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.
› Verified 4 days ago
Dr. Cody Michael Ghents, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 24700 N 67th Ave, Peoria, AZ 85383 Phone: 623-259-3458 | |
Cactus Chiropractic Llc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 7440 W Cactus Rd, A19, Peoria, AZ 85381 Phone: 623-878-9388 Fax: 623-878-9114 | |
Nicole Renee Maddox, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 15256 N 75th Ave Ste 360, Peoria, AZ 85381 Phone: 623-486-2424 Fax: 623-486-4324 | |
Lori Fininis, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 8440 W Thunderbird Rd, Peoria, AZ 85381 Phone: 602-247-8626 Fax: 602-247-8646 | |
Dr. Bradley Green Matson, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 7226 W Columbine Dr, Peoria, AZ 85381 Phone: 602-809-6781 Fax: 602-235-2035 | |
Dr. Stockton Butterfield, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 6750 W Thunderbird Rd, Peoria, AZ 85381 Phone: 602-368-1333 |